Patents Assigned to BEIGENE SWITZERLAND GMBH
-
Publication number: 20240122932Abstract: The present disclosure provides methods of treating B-cell malignancy in a subject with a Bcl-2 inhibitor, in particularly 2-((1H-pyrrolo[2,3-b]pyridin-5-yl)oxy)-N-((4-((((1r,4r)-4-hydroxy-4-methylcyclohexyl)methyl)amino)-3-nitrophenyl)sulfonyl)-4-(2-((S)-2-(2-isopropylphenyl)pyrrolidin-1-yl)-7-azaspiro[3.5]nonan-7-yl)benzamide or a pharmaceutically acceptable salt thereof, or its combination with a Bruton's tyrosine kinase (BTK) inhibitor, particularly (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo-[1,5-a]pyrimidine-3-carboxamide or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: November 30, 2023Publication date: April 18, 2024Applicant: BeiGene Switzerland GmbHInventors: James D. Hilger, Jane Huang, David Simpson
-
Publication number: 20240101564Abstract: The present invention relates to salts of a PI3Kdelta inhibitor (referred to as “Compound A” hereinafter), preferably fumarate, and the crystalline forms thereof. The present invention also relates to the process of preparation and uses of the salts and crystalline forms of Compound A.Type: ApplicationFiled: November 22, 2023Publication date: March 28, 2024Applicant: BeiGene Switzerland GmbHInventors: Jing LI, Xiaosong YU, Xiaopeng CAI, Zhiwei WANG
-
Patent number: 11911386Abstract: Provided herein is a method of treating a patient having a B-cell proliferative disorder, the method comprising administering to the patient zanubrutinib, or a pharmaceutically acceptable salt thereof, wherein the patient is characterized by being administered with a moderate CYP3A inducer. In one embodiment, zanubrutinib is administered at a dose of about 320 mg twice a day, or at a total daily dose of about 640 mg.Type: GrantFiled: May 31, 2023Date of Patent: February 27, 2024Assignee: BeiGene Switzerland GmbHInventors: Jason Paik, Tommi Salmi, Ying Ou, Motohisa Takai
-
Patent number: 11896596Abstract: Provided herein is a method of treating a patient having a B-cell proliferative disorder, the method comprising administering to the patient zanubrutinib, or a pharmaceutically acceptable salt thereof, wherein the patient is characterized by being administered with a moderate CYP3A inducer. In one embodiment, zanubrutinib is administered at a dose of about 320 mg twice a day, or at a total daily dose of about 640 mg.Type: GrantFiled: June 6, 2023Date of Patent: February 13, 2024Assignee: BeiGene Switzerland GmbHInventors: Jason Paik, Tommi Salmi, Ying Ou, Motohisa Takai
-
Patent number: 11884674Abstract: The present invention relates to a crystalline form of (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide for inhibiting Btk, methods of preparation thereof and pharmaceutical compositions, and use of the crystalline form above in the treatment of a disease, or in the manufacturing of a medicament for the treatment of a disease.Type: GrantFiled: July 6, 2022Date of Patent: January 30, 2024Assignee: BEIGENE SWITZERLAND GMBHInventors: Zhiwei Wang, Yunhang Guo, Gongyin Shi, Lai Wang
-
Patent number: 11851437Abstract: The present invention relates to a crystalline form of (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide for inhibiting Btk, methods of preparation thereof and pharmaceutical compositions, and use of the crystalline form above in the treatment of a disease, or in the manufacturing of a medicament for the treatment of a disease.Type: GrantFiled: September 2, 2022Date of Patent: December 26, 2023Assignee: BEIGENE SWITZERLAND GMBHInventors: Zhiwei Wang, Yunhang Guo, Gongyin Shi
-
Patent number: 11814389Abstract: The present invention relates to a crystalline form of (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide for inhibiting Btk, methods of preparation thereof and pharmaceutical compositions, and use of the crystalline form above in the treatment of a disease, or in the manufacturing of a medicament for the treatment of a disease.Type: GrantFiled: July 6, 2022Date of Patent: November 14, 2023Assignee: BEIGENE SWITZERLAND GMBHInventors: Zhiwei Wang, Yunhang Guo, Gongyin Shi
-
Patent number: 11786529Abstract: Disclosed herein is a method for the prevention, delay of progression or treatment of indolent or aggressive B-cell lymphomas in an individual in need thereof, comprising administering a Btk inhibitor (in particularly (S)-7-(1-actyloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo-[1,5-a]pyrimidine-3-carboxamide or a pharmaceutically acceptable salt thereof) in combination with an anti-PD-1 antibody. The potent and selective BTK inhibitor in combination with the anti-PD-1 antibody have a manageable toxicity profile in patients with indolent and aggressive lymphomas.Type: GrantFiled: November 29, 2018Date of Patent: October 17, 2023Assignee: BEIGENE SWITZERLAND GMBHInventors: James Hilger, Xiaoping Zhang, Shibao Feng, Sunhee Ro, Jane Huang
-
Patent number: 11786531Abstract: Provided herein is a method of treating a patient having a B-cell proliferative disorder, the method comprising administering to the patient zanubrutinib, or a pharmaceutically acceptable salt thereof, wherein the patient is characterized by being administered with a moderate CYP3A inducer. In one embodiment, zanubrutinib is administered at a dose of about 320 mg twice a day, or at a total daily dose of about 640 mg.Type: GrantFiled: January 19, 2023Date of Patent: October 17, 2023Assignee: BeiGene Switzerland GmbHInventors: Jason Paik, Tommi Salmi, Ying Ou
-
Patent number: 11701357Abstract: Disclosed herein is a method for the prevention, delay of progression or treatment of cancer in a subject, comprising administering to the subject in need thereof a Btk inhibitor, particularly, (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide or a pharmaceutically acceptable salt thereof, in combination with an immune checkpoint inhibitor or a targeted therapy agent. Also, disclosed a pharmaceutical combination comprising a Btk inhibitor, particularly, (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide or a pharmaceutically acceptable salt thereof, in combination with an immune checkpoint inhibitor, or a targeted therapy agent and the use thereof.Type: GrantFiled: August 18, 2017Date of Patent: July 18, 2023Assignee: BEIGENE SWITZERLAND GMBHInventors: Nan Hu, Lai Wang, Jing Song, Tong Zhang, Kang Li, Lusong Luo, Min Wei, Zhiwei Wang, Yunhang Guo
-
Patent number: 11673951Abstract: Provided are antibodies that specifically bind to Programmed Death-1 (PD1, Pdcd-1, or CD279) and inhibit PD1-mediated cellular signaling and activities in immune cells, antibodies binding to a set of amino acid residues required for its ligand binding, and uses of these antibodies to treat or diagnose cancer, infectious diseases or other pathological disorders modulated by PD1-mediated functions.Type: GrantFiled: November 14, 2019Date of Patent: June 13, 2023Assignee: BEIGENE SWITZERLAND GMBHInventors: Kang Li, Tong Zhang, Jing Song, Lanlan Xu, Qi Liu, Hao Peng
-
Patent number: 11591340Abstract: The present invention relates to a crystalline form of (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide for inhibiting Btk, methods of preparation thereof and pharmaceutical compositions, and use of the crystalline form above in the treatment of a disease, or in the manufacturing of a medicament for the treatment of a disease.Type: GrantFiled: May 10, 2022Date of Patent: February 28, 2023Assignee: BEIGENE SWITZERLAND GMBHInventors: Zhiwei Wang, Yunhang Guo, Gongyin Shi, Lai Wang
-
Patent number: 11534431Abstract: Disclosed herein is a pharmaceutical combination for use in the prevention, delay of progression or treatment of cancer, wherein the pharmaceutical combination exhibits a synergistic efficacy. The pharmaceutical combination comprises a humanized antagonist monoclonal antibody against PD- and a RAF inhibitor. Also disclosed herein is a combination for use in the prevention, delay of progression or treatment of cancer in a subject, comprising administering to the subject a therapeutically effective amount of a humanized antagonist monoclonal antibody against PD-1 and a therapeutically effective amount of a RAF inhibitor.Type: GrantFiled: November 16, 2020Date of Patent: December 27, 2022Assignee: BEIGENE SWITZERLAND GMBHInventors: Jing Song, Lai Wang, Kang Li, Tong Zhang, Lusong Luo, Min Wei, Zhiyu Tang, Guoliang Zhang, Changyou Zhou
-
Patent number: 11186637Abstract: Provided are antibodies that specifically bind to Programmed Death-1 (PD1, Pdcd-1, or CD279) and inhibit PD1-mediated cellular signaling and activities in immune cells, antibodies binding to a set of amino acid residues required for its ligand binding, and uses of these antibodies to treat or diagnose cancer, infectious diseases or other pathological disorders modulated by PD1-mediated functions.Type: GrantFiled: January 21, 2021Date of Patent: November 30, 2021Assignee: BEIGENE SWITZERLAND GMBHInventors: Kang Li, Tong Zhang, Jing Song, Lanlan Xu, Qi Liu, Hao Peng
-
Patent number: 11142528Abstract: The invention is fused heterocyclic compounds of formula (I), and salts thereof, compositions thereof, and methods of use therefor. In particular, disclosed herein are certain fused heterocyclic compounds that can be useful for inhibiting protein kinase, including Bruton's tyrosine kinase (Btk), and for treating disorders mediated thereby.Type: GrantFiled: January 10, 2020Date of Patent: October 12, 2021Assignee: BEIGENE SWITZERLAND GMBHInventors: Zhiwei Wang, Yunhang Guo
-
Patent number: 10927117Abstract: The present invention relates to a crystalline form of (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide for inhibiting Btk, methods of preparation thereof and pharmaceutical compositions, and use of the crystalline form above in the treatment of a disease, or in the manufacturing of a medicament for the treatment of a disease.Type: GrantFiled: August 15, 2017Date of Patent: February 23, 2021Assignee: BEIGENE SWITZERLAND GMBHInventors: Zhiwei Wang, Yunhang Guo, Gongyin Shi
-
Patent number: 10570139Abstract: The invention is fused heterocyclic compounds of formula (I), and salts thereof, compositions thereof, and methods of use therefor. In particular, disclosed herein are certain fused heterocyclic compounds that can be useful for inhibiting protein kinase, including Bruton's tyrosine kinase (Btk), and for treating disorders mediated thereby.Type: GrantFiled: May 3, 2018Date of Patent: February 25, 2020Assignee: BEIGENE SWITZERLAND GMBHInventors: Zhiwei Wang, Yunhang Guo
-
Patent number: 10519235Abstract: Provided are antibodies that specifically bind to Programmed Death-1 (PD1, Pdcd-1, or CD279) and inhibit PD1-mediated cellular signaling and activities in immune cells, antibodies binding to a set of amino acid residues required for its ligand binding, and uses of these antibodies to treat or diagnose cancer, infectious diseases or other pathological disorders modulated by PD1-mediated functions.Type: GrantFiled: May 14, 2018Date of Patent: December 31, 2019Assignee: BEIGENE SWITZERLAND GMBHInventors: Kang Li, Tong Zhang, Jing Song, Lanlan Xu, Qi Liu, Hao Peng
-
Patent number: 9988450Abstract: Provided are antibodies that specifically bind to Programmed Death-1 (PD1, Pdcd-1, or CD279) and inhibit PD1-mediated cellular signaling and activities in immune cells, antibodies binding to a set of amino acid residues required for its ligand binding, and uses of these antibodies to treat or diagnose cancer, infectious diseases or other pathological disorders modulated by PD1-mediated functions.Type: GrantFiled: November 2, 2017Date of Patent: June 5, 2018Assignee: BEIGENE SWITZERLAND GMBHInventors: Kang Li, Tong Zhang, Jing Song, Lanlan Xu, Qi Liu, Hao Peng